Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Clinical Trials Endpoints In Oncology Introduction | 7 | 2 |
| Introduction | 7 | 1 |
| GBI Research Report Guidance | 8 | 1 |
| Clinical Trials Endpoints In Oncology Market Overview | 9 | 4 |
| Endpoints Used for Regular Approval | 9 | 2 |
| Survival | 11 | 1 |
| Progression-free survival | 11 | 1 |
| Tumor Response, Response Duration, and Time-to-Tumor Progression | 12 | 1 |
| DFS | 12 | 1 |
| Clinical Trials Endpoints in Oncology Therapeutic Analysis | 13 | 81 |
| Colorectal Cancer | 13 | 1 |
| Major Marketed Drug Analysis | 13 | 2 |
| Profiling of Major Marketed Products | 15 | 1 |
| Avastin (bevacizumab) | 15 | 1 |
| Erbitux (cetuximab) | 16 | 1 |
| Xeloda (capecitabine) | 17 | 1 |
| Vectibix (panitumumab) | 18 | 1 |
| Eloxatin (oxaliplatin) | 19 | 2 |
| Camptosar (irinotecan) | 21 | 1 |
| Phase III Molecules Analysis | 22 | 1 |
| Most Promising Drugs Profiles | 23 | 1 |
| Aflibercept | 23 | 1 |
| Brivanib | 24 | 5 |
| Phase II Molecules Analysis | 29 | 6 |
| Terminated Trials | 35 | 1 |
| Vectibix Treatment Discontinued Due to Safety Issues, Metastatic Colorectal Cancer | 35 | 1 |
| Prostate Cancer | 36 | 1 |
| Major Marketed Drug Analysis | 36 | 2 |
| Profiling of Major Marketed Products | 38 | 1 |
| Taxotere (docetaxel) | 38 | 1 |
| Casodex (Bicalutamide) | 39 | 1 |
| Zoladex (Goserelin) | 40 | 1 |
| Provenge (sipuleucel-T) | 41 | 2 |
| Eligard (leuprolide acetate) | 43 | 1 |
| Prostap (leuprolide acetate) | 44 | 1 |
| Firmagon (degarelix) | 45 | 1 |
| Vantas (histrelin) | 46 | 2 |
| Novantrone (mitoxantrone hydrochloride) | 48 | 1 |
| Trelstar (triptorelin) | 49 | 1 |
| Phase III Molecules Analysis | 50 | 1 |
| Most Promising Drugs Profiles | 51 | 1 |
| Aflibercept (VEGF Trap) | 51 | 1 |
| Ipilimumab | 52 | 1 |
| Abiraterone Acetate (CB7630) | 53 | 1 |
| Zibotentan (ZD4054) | 54 | 4 |
| Phase II Molecules Analysis | 58 | 5 |
| Terminated Trials | 63 | 1 |
| Pfizer Discontinues Sutent Prostate Cancer Trial | 63 | 1 |
| Head and Neck Cancer Therapeutics | 63 | 1 |
| Major Marketed Drug Analysis | 63 | 2 |
| Profiling of Major Marketed Products | 65 | 1 |
| Erbitux (cetuximab) | 65 | 1 |
| Taxotere (docetaxel) | 66 | 1 |
| Oncorine (H101, Modified Adenovirus) | 67 | 1 |
| Gendicine (Recombinant Human Ad-P53) | 68 | 1 |
| Phase III Molecules Analysis | 68 | 1 |
| Tykerb/ Tyverb (Lapatinib Ditosylate) | 69 | 1 |
| Reolysin | 70 | 3 |
| Phase II molecules Analysis | 73 | 3 |
| Terminated Trials | 76 | 1 |
| Iressa (AstraZeneca) Failed to Prolong Survival and Increased Bleeding Events in the Treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN) | 76 | 1 |
| Bivatuzumab Mertansine (Boehringer Ingelheim GmbH; Immunogen, Inc) Clinical Development Discontinued | 76 | 1 |
| Ovarian Cancer | 77 | 1 |
| Major Marketed Drug Analysis | 77 | 1 |
| Profiling of Major Marketed Products | 78 | 1 |
| Altretamine (hexalen) | 78 | 1 |
| Gemcitabine (gemzar) | 78 | 1 |
| Hycamtin (topotecan hydrochloride) | 79 | 1 |
| Yondelis | 80 | 1 |
| Phase III molecules Analysis | 81 | 1 |
| Avastin (RG435, bevacizumab) | 82 | 1 |
| Opaxio | 83 | 1 |
| Abagovomab | 84 | 1 |
| Telcyta (canfosfamide HCl) | 85 | 1 |
| Karenitecin (BNP 1350) | 86 | 3 |
| Phase II Molecules Analysis | 89 | 4 |
| Terminated Trials | 93 | 1 |
| OvaRex (United Therapeutics Corporation) Fail to Meet Primary Endpoint in Advanced Ovarian Cancer | 93 | 1 |
| Pemtumomab (Antisoma, Hoffmann-La Roche, Inc.) Dsicontinued the Study in Advanced Ovarian Cancer | 93 | 1 |
| Clinical Trials Endpoints In Oncology New Trends and Technologies | 94 | 1 |
| Microsatellite Instability (MSI) as a Diagnostic Tool in Colorectal Cancer | 94 | 1 |
| New Biomarker for Aggressive Prostate Cancer | 94 | 1 |
| Clinical Trials Endpoints In Oncology Company Profiling | 95 | 20 |
| F. Hoffmann La Roche | 95 | 1 |
| Business Description | 95 | 1 |
| Financial Overview | 95 | 1 |
| Major Oncology Products | 96 | 1 |
| Avastin (bevacizumab) | 96 | 1 |
| Xeloda (capecitabine) | 97 | 1 |
| Bristol-Myers Squibb | 98 | 1 |
| Business Description | 98 | 1 |
| Financial Overview | 98 | 1 |
| Major Oncology Products | 98 | 1 |
| Erbitux (cetuximab) | 98 | 2 |
| Sanofi-Aventis | 100 | 1 |
| Business Description | 100 | 1 |
| Financial Overview | 100 | 1 |
| Major Oncology Products | 101 | 1 |
| Taxotere (docetaxel) | 101 | 1 |
| Eloxatin (oxaliplatin) | 102 | 1 |
| Merck KGaA | 103 | 1 |
| Business Description | 103 | 1 |
| Financial Overview | 104 | 1 |
| Major Oncology Products | 104 | 1 |
| Erbitux (cetuximab) | 104 | 1 |
| Pfizer Inc. | 105 | 1 |
| Business Description | 105 | 1 |
| Financial Overview | 106 | 1 |
| Major Oncology Products | 106 | 1 |
| Camptosar (irinotecan) | 106 | 1 |
| AstraZeneca | 107 | 1 |
| Business Description | 107 | 1 |
| Financial Overview | 108 | 1 |
| Major Oncology Products | 109 | 1 |
| Casodex (Bicalutamide) | 109 | 1 |
| Zoladex (Goserelin) | 110 | 1 |
| Clinical Study Details | 111 | 1 |
| Takeda Pharmaceuticals | 111 | 1 |
| Business Description | 111 | 1 |
| Financial Overview | 111 | 1 |
| Major Oncology Products | 111 | 1 |
| Vectibix (panitumumab) | 111 | 2 |
| GlaxoSmithKline plc. | 113 | 1 |
| Business Description | 113 | 1 |
| Financial Overview | 113 | 1 |
| Major Oncology Products | 114 | 1 |
| Hycamtin (topotecan hydrochloride) | 114 | 1 |
| Clinical Trials Endpoints In Oncology Appendix | 115 | 6 |
| Market Definitions | 115 | 1 |
| Abbreviations | 115 | 3 |
| Research Methodology | 118 | 2 |
| Coverage | 118 | 1 |
| Secondary Research | 118 | 1 |
| Primary Research | 119 | 1 |
| Expert Panel Validation | 119 | 1 |
| Contact Us | 119 | 1 |
| Disclaimer | 120 | 1 |
| Sources | 120 | 1 |